Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) — repository of SEC EDGAR quarterly and annual filing cover-page excerpts. Provided source text is limited to filing metadata; no financial statements, MD&A, guidance, or material disclosures are included in these excerpts.
Past bets that played out
The single highlighted call notes that the NTLA 10‑Q excerpt (quarter ended 2026‑03‑31) is only the SEC cover page/filing-status section and therefore provides no basis for trading on fundamentals.
This excerpt of NTLA’s 10‑Q (quarter ended 2026‑03‑31) contains only the SEC cover page/filing status and listing information, with no financial statements, guidance, program updates, risks, cash runway, or material events. It is therefore not actionable for trading on fundamentals.
What this channel is watching now
We are tracking Intellia Therapeutics, Inc. (NTLA) by monitoring its SEC EDGAR filings. The available excerpt is limited to the cover page of the company’s Form 10‑Q for the quarter ended 2026‑03‑31 and contains only listing and filing metadata.
Latest videos and market context
No video content is associated with these filing excerpts; source material consists solely of SEC EDGAR cover-page text.
SNBR 10-Q report for 2026-04-04
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
SOUN 10-Q report for 2026-03-31
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
WEAT 10-Q report for 2026-03-31
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
ACHR 10-Q report for 2026-03-31
The provided text is only the cover/header portion of Archer Aviation’s Form 10‑Q for the quarter ended 2026‑03‑31 (issuer identity, exchange listing, and securities outstanding). It contains no operating/financial results, guidance, liquidity details, backlog, or risk-factor updates—so it is minimally actionable for trading beyond basic security identifiers and a generic dilution/optionality consideration from warrants.
Proof-backed call history
This author page aggregates recent SEC filing-header excerpts. Each excerpt in the recent set (SNBR, SOUN, WEAT, ACHR, NTLA) is a cover/header section of a Form 10‑Q and therefore lacks financial statements, MD&A, guidance, risk updates, liquidity details, or other material disclosures.
This excerpt of NTLA’s 10‑Q (quarter ended 2026‑03‑31) contains only the SEC cover page/filing status and listing information, with no financial statements, guidance, program updates, risks, cash runway, or material events. It is therefore not actionable for trading on fundamentals.
About this channel
These entries are sourced from SEC EDGAR quarterly and annual company filings. The supplied excerpts are limited to filing metadata (issuer identity, ticker, exchange, address, and filing status) and do not include substantive financial or operational content.
SEC EDGAR quarterly and annual company filings
Most recognized assets
Unlock the full track record
If you need full financial statements, MD&A, or other substantive disclosure for NTLA or any other issuer, retrieve the complete SEC filing from EDGAR (https://www.sec.gov/edgar) or request a complete filing excerpt.